<DOC>
	<DOC>NCT00055146</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and effectiveness of ONTAK in previously treated patients with chronic lymphocytic leukemia (CLL)</brief_summary>
	<brief_title>Study of ONTAK in Patients With B-Cell Chronic Lymphocytic Leukemia (CLL)</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Lymphoid</mesh_term>
	<mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
	<mesh_term>Denileukin diftitox</mesh_term>
	<criteria>Patients with Bcell Chronic Lymphocytic Leukemia, Rai Stage 0II with indication for treatment by NCI Working Group Criteria or Rai Stage III or IV. Patients must have received at least one prior purine analoguebased chemotherapy regimen. ECOG Performance Status of 0, 1, or 2. Female patients cannot be pregnant and must use birth control during the course of the study and for three weeks after the study ends. Prior treatment with ONTAK (DAB389IL2) or DAB486IL2. Received any therapy for CLL within 35 days prior to study entry.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2009</verification_date>
</DOC>